AZ D5180C00018 DESTINATION: A multicentre double blind randomized placebo controlled parallel group phase 3 safety extension study to evaluate safety & tolerability of Tezepelumab

Administered By

Contributors

Start/End

  • July 12, 2019 - July 14, 2021